Zinger Key Points
- D.C.'s attempt to establish its own cannabis market faces another hurdle as House Committee blocks key amendments.
- Proposed protections for federal job applicants against cannabis testing stymied in Congress.
- Justice Department's scrutiny of state marijuana laws and research barriers ignites a fresh debate on the direction of U.S. drug policy.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
The House Rules Committee, a key legislative panel, has rejected amendments that would have permitted cannabis sales in Washington, D.C. and barred cannabis testing for applicants to federal jobs.
What Happened
The amendments, part of the appropriations bill, were not given the green light for floor votes by the GOP-controlled committee, reported Marijuana Moment. This continues a trend where the panel has consistently blocked various cannabis reform measures from reaching the full House for a vote.
The D.C. amendment, put forward by Reps. Eleanor Holmes Norton (D-DC), Earl Blumenauer (D-OR) and Barbara Lee (D-CA), aimed to remove a longstanding rider that has prevented the district from using local funds to create a legal cannabis marketplace.
Despite D.C. voters approving legalization in 2014, this rider has been a fixture in budget proposals by leaders from both parties and the President.
Protection For Federal Employees’ Cannabis Use: An Unsuccessful Effort
Another amendment by Rep. Robert Garcia (D-CA) sought to protect federal employees from being tested for cannabis use, a reform initiative he pursued at the city level while mayor of Long Beach.
These actions in Congress reflect an evolving perspective on cannabis and psychedelics as lawmakers and federal agencies begin to consider new approaches to drug regulation and research.
Ongoing Debate Over Federal Cannabis Policy
This decision by the House committee is part of an ongoing legislative conversation around marijuana policies. Prior to this, Congress had also considered two completely opposed amendments, one to safeguard states with legal cannabis programs and another to prevent President Biden from rescheduling cannabis.
Federal Policy Implications On State Cannabis Law And Research
A congressional committee urged the Department of Justice to evaluate the ‘adequacy’ of state cannabis laws and to address obstacles to federal research.
This push for clarity and scientific understanding signifies the importance of evidence-based policymaking in an era where states are increasingly diverging from federal law regarding drug policy.
The Complex Road To Legalization
The blockage of these recent amendments, especially following the DOJ’s call for research and Ohio voters’ strong support for a marijuana legalization ballot initiative, underscores the often contradictory approach to cannabis regulation at different levels of government in the United States.
Read more at Marijuana Moment.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!